High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination

• Published in: Virology (New York, N.Y.) Vol. 387; no. 2; pp. 414 - 426
• Main Authors: Davis, Katie L., Gray, Elin S., Moore, Penny L., Decker, Julie M., Salomon, Aidy, Montefiori, David C., Graham, Barney S., Keefer, Michael C., Pinter, Abraham, Morris, Lynn, Hahn, Beatrice H., Shaw, George M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.05.2009
• Subjects: Acute Disease; Acute HIV-1 infection; Amino Acid Sequence; Antibody Specificity; Cross Reactions; Epitopes - genetics; Epitopes - immunology; Female; HIV Antibodies - blood; HIV Antibodies - immunology; HIV Envelope Protein gp120 - genetics; HIV Envelope Protein gp120 - immunology; HIV Infections - blood; HIV Infections - immunology; HIV-1; HIV-1 - immunology; HIV-2; HIV-2 - immunology; Human immunodeficiency virus 1; Human immunodeficiency virus 2; Humans; Infectious Disease; Molecular Sequence Data; Neutralization Tests; Neutralizing antibodies; Peptide Fragments - genetics; Peptide Fragments - immunology; Sequence Alignment; Vaccination; Variable loop 3; HIV-1; Variable loop 3; HIV-2; Neutralizing antibodies; Acute HIV-1 infection

Identifying the earliest neutralizing antibody specificities that are elicited following infection or vaccination by HIV-1 is an important objective of current HIV/AIDS vaccine research. We have shown previously that transplantation of HIV-1 V3 epitopes into an HIV-2 envelope (Env) scaffold provides...